These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4197045)

  • 1. [Severe serogenic hemolytic anemia caused by anti-D fraction in factor VIII concentrate].
    Schricker KT; Schrenk KH
    Thromb Diath Haemorrh; 1972 Jul; 27(3):523-8. PubMed ID: 4197045
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemolytic anemia and F. VIII concentrate.
    Girelli G
    Eur J Haematol; 1989 Apr; 42(4):414. PubMed ID: 2498124
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemolysis caused by factor VIII concentrates.
    Orringer EP; Koury MJ; Blatt PM; Roberts HR
    Arch Intern Med; 1976 Sep; 136(9):1018-20. PubMed ID: 962445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostasis. II. The use of factor VIII concentrates in the therapy of hemophilia.
    Davis RB
    Nebr State Med J; 1971 Jun; 56(6):219-24. PubMed ID: 4253029
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemophiliac with hemolytic anemia resulting from factor VIII concentrate.
    Soni NS; Patel AR; Vohra RM; Shah PC
    Acta Haematol; 1977; 58(5):294-7. PubMed ID: 413305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Case of hemolytic anemia following treatment with cryobulin].
    Pluta A; Kniaź M; Kowalewski J
    Wiad Lek; 1980 Apr; 33(7):555-7. PubMed ID: 6771920
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemolytic anemia due to anti-B in antihemophiliac factor concentrates.
    Ashenhurst JB; Langehennig PL; Seeler RA; Telfer MC
    J Pediatr; 1976 Feb; 88(2):257-8. PubMed ID: 1249687
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study on the levels of anti-A, anti-B isoagglutinin titer in various kinds of concentrates for hemophilia treatment--with special regard to the manufacturing process of factor VIII concentrate].
    Tomita Y; Inagaki M; Taki M; Miura T; Saito N; Sato R; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Feb; 26(2):166-70. PubMed ID: 3927035
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemolytic anemia caused by infusion of factor VIII concentrates--a case report of hemophilia A with intracranial hemorrhage].
    Fukazawa K; Okuyama T; Manabe H; Kanaya J
    Rinsho Ketsueki; 1983 Jul; 24(7):892-6. PubMed ID: 6415317
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired hemolytic anemia and thrombocytopenia (Evans' syndrome) in hemophilia.
    Harris PJ; Kessler CM; Lessin LS
    N Engl J Med; 1983 Jul; 309(1):50. PubMed ID: 6406894
    [No Abstract]   [Full Text] [Related]  

  • 13. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 14. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
    Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute anemia with factor VIII therapy.
    King EG; Clarke ME; Buchanan DI
    Ann Intern Med; 1972 Aug; 77(2):323-4. PubMed ID: 4641666
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
    Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
    Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Causes of transfusional hemolytic reactions in ABO and Rh blood group systems].
    Gambella O; Peracino A
    Quad Sclavo Diagn; 1971 Sep; 7(3):601-17. PubMed ID: 5006085
    [No Abstract]   [Full Text] [Related]  

  • 20. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F; Stein P
    Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.